Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Xenon, with a price target of $55.00. According to TipRanks, Chico ...

Wedbush Sticks to Its Buy Rating for Xenon (XENE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB) w...

Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)

Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals has submitted a New Drug Application to the U.S. Food and Drug Administration for ...

Xenon Files FDA NDA for Azetukalner in Focal Seizures and Pauses New Psychiatry Enrollment

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xenon (XENE) and Immix Biopharma (IMMX) with bullish...

Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Immix Biopharma (IMMX)

Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals will showcase six presentations at the European Epilepsy Congress 2026 in Athens, ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$57.35	+1.04%	1.83M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$57.35	+1.0%	1.83M
3
4
5
6

XENE

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel